CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

143 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to test whether early central nervous system (CNS) prophylaxis given at the beginning of therapy for young high risk diffuse large B-cell lymphoma (DLBCL) patients is feasible and could reduce the risk of CNS relapses. Early CNS prophylaxis with two courses high dose methotrexate (HD-MTX) in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednison (R-CHOP) is followed by four courses of R-CHOP14 and etoposide (E) and one course of HD-Ara-C. In addition the patients will receive three courses of liposomal cytarabine intrathecally. The results will be compared to a recent Nordic CRY-04 study. Shifting of CNS prophylaxis to the beginning of the therapy offers a potential to overcome the subclinical disease and thus reduce the risk of early clinical CNS recurrence. As flow cytometry (FCM) can improve the sensitivity for detecting occult leptomeningeal disease over cytology , FCM from cerebrospinal fluid will be incorporated into the staging procedures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)

NCT01502982

Diffuse Large B-Cell Lymphoma

COMPLETED PHASE2

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

NCT03293173

Lymphoma, Large B-Cell, Diffuse

ACTIVE_NOT_RECRUITING PHASE2

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

NCT03719560

Diffuse Large B Cell Lymphoma

WITHDRAWN PHASE2

CNS Prophylaxis in Diffuse Large B-cell Lymphoma

NCT02777736

Diffuse Large B-cell Lymphoma

UNKNOWN PHASE3

High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL

NCT03123718

DLBCL

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CNS prophylaxis

Group Type EXPERIMENTAL

liposomal cytarabine

Intervention Type DRUG

50 mg intrathecally three times

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

liposomal cytarabine

50 mg intrathecally three times

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Depocyte

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 - \< 65 years. Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) based on WHO 2008 Lymphoma Classification
* Follicular lymphomas (FLs) grade 3b is allowed

Patients in at least stage II with age adjusted international prognostic score (IPI score) of 2 or 3:

* Stage III /IV and elevated LDH
* Stage III/IV and WHO performance status 2 - 3
* Stage II and elevated LDH and WHO performance status 2 - 3 And/or patients with
* More than one extranodal site
* Testicular lymphoma, stage IIE and higher
* Paranasal sinus and orbital lymphoma with destruction of bone
* Large cell infiltration of the bone marrow

Exclusion Criteria

* Severe cardiac disease: cardiac function grade 3-4
* Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule
* Pregnancy/lactation
* Men and women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for six months after completion of treatment
* Patients with other severe medical problems and with an expected short survival for non-lymphoma reasons
* Known HIV positivity
* Uncontrolled infectious disease, including meningeal infection
* Active cancer except basal cell carcinoma and cervical carcinoma in situ during the last five years
* Earlier treatment containing anthracyclins
* Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol
* CNS disease as diagnosed by MRI or cerebrospinal fluid (CSF) cytology. Positive CSF flow cytometry below diagnostic threshold level by cytology is allowed
* Pleural or peritoneal fluid that cannot be drained safely
* Hypersensitivity to the active substance or any of the other ingredients
* Patients participating in other clinical studies, unless followed for survival

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No